🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 14/03/2014 | 77,57 | 79,76 | 76,90 | 78,32 | +0,59% | 3,69% | 1.179.300 |
| 13/03/2014 | 79,92 | 80,00 | 77,11 | 77,86 | -2,52% | 3,62% | 1.130.400 |
| 12/03/2014 | 78,64 | 80,15 | 78,05 | 79,87 | +0,86% | 2,67% | 946.300 |
| 11/03/2014 | 79,99 | 80,56 | 78,48 | 79,19 | -0,58% | 2,60% | 1.201.000 |
| 10/03/2014 | 79,60 | 79,92 | 77,92 | 79,65 | -0,36% | 2,51% | 1.316.300 |
| 07/03/2014 | 80,51 | 81,60 | 76,31 | 79,94 | +0,00% | 6,57% | 1.706.700 |
| 06/03/2014 | 83,51 | 83,59 | 79,33 | 79,94 | -3,64% | 5,10% | 1.522.600 |
| 05/03/2014 | 83,27 | 83,42 | 82,08 | 82,96 | -0,19% | 1,61% | 914.200 |
| 04/03/2014 | 82,54 | 83,82 | 81,65 | 83,12 | +1,91% | 2,63% | 1.204.800 |
| 03/03/2014 | 80,25 | 83,25 | 79,57 | 81,56 | +0,87% | 4,59% | 1.134.700 |
| 28/02/2014 | 83,48 | 84,25 | 79,33 | 80,86 | -2,77% | 5,89% | 1.786.100 |
| 27/02/2014 | 84,24 | 84,57 | 82,39 | 83,16 | -0,94% | 2,59% | 1.374.800 |
| 26/02/2014 | 84,63 | 85,22 | 83,45 | 83,95 | -0,79% | 2,09% | 1.128.900 |
| 25/02/2014 | 84,21 | 85,98 | 83,57 | 84,62 | +0,80% | 2,86% | 1.292.700 |
| 24/02/2014 | 85,29 | 85,29 | 83,76 | 83,95 | -1,01% | 1,79% | 1.287.300 |
| 21/02/2014 | 84,44 | 86,12 | 83,48 | 84,81 | +0,95% | 3,13% | 1.911.500 |
| 20/02/2014 | 83,07 | 84,46 | 81,86 | 84,01 | +1,71% | 3,13% | 1.234.400 |
| 19/02/2014 | 81,96 | 84,41 | 81,61 | 82,60 | +0,73% | 3,42% | 1.241.500 |
| 18/02/2014 | 82,03 | 83,30 | 81,92 | 82,00 | +0,48% | 1,68% | 2.043.400 |
| 14/02/2014 | 84,38 | 84,98 | 81,05 | 81,61 | -3,99% | 4,66% | 1.772.000 |
| 13/02/2014 | 83,39 | 85,65 | 82,03 | 85,00 | +1,31% | 4,34% | 1.492.700 |
| 12/02/2014 | 84,54 | 85,89 | 83,49 | 83,90 | -1,27% | 2,84% | 1.265.800 |
| 11/02/2014 | 82,28 | 85,00 | 81,56 | 84,98 | +3,42% | 4,18% | 1.439.000 |
| 10/02/2014 | 81,10 | 82,30 | 80,95 | 82,17 | +0,93% | 1,66% | 1.590.400 |
| 07/02/2014 | 78,69 | 81,46 | 78,23 | 81,41 | +4,14% | 4,10% | 1.465.400 |
| 06/02/2014 | 76,45 | 79,24 | 76,24 | 78,17 | +0,98% | 3,92% | 1.685.300 |
| 05/02/2014 | 78,12 | 78,73 | 75,89 | 77,41 | -2,20% | 3,64% | 1.843.600 |
| 04/02/2014 | 76,95 | 79,70 | 76,78 | 79,15 | +1,96% | 3,79% | 2.141.200 |
| 03/02/2014 | 78,50 | 79,84 | 77,16 | 77,63 | -1,78% | 3,41% | 2.403.900 |
| 31/01/2014 | 80,70 | 81,00 | 78,96 | 79,04 | -3,79% | 2,53% | 1.572.700 |